At its Meeting on 23 May 2022, the Transparency Council adopted Position No. 50/2022 on on the evaluation of Tecentriq (atezolizumabum) under the drug programme: “Treatment of non-small-cell or small-cell lung cancer (ICD-10 C34)”.
At its Meeting on 23 May 2022, the Transparency Council adopted Position No. 50/2022 on on the evaluation of Tecentriq (atezolizumabum) under the drug programme: “Treatment of non-small-cell or small-cell lung cancer (ICD-10 C34)”.